Short answer
Definium Therapeutics, Inc. (DFTX) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA breakthrough designation granted to DT120 ODT for major depressive disorder.
Definium Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA breakthrough designation granted to DT120 ODT for major depressive disorder
- Potentially faster FDA development and review pathway for DT120 ODT
- Regulatory milestone may improve program visibility and strategic partnering prospects
- Details on clinical data and development plans in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- FDA Breakthrough Therapy designation for DT120 in MDD, accelerating potential development and review
- Phase 3 Emerge: 8.1-point placebo-adjusted MADRS improvement at Week 6, p<0.0001
- Efficacy remained durable through Week 12 after a single 100 µg dose
- Second FDA Breakthrough Therapy designation, expanding DT120’s regulatory momentum across MDD and GAD
- Key risks: controlled-substance scheduling, clinical approval, funding needs, treatment-site capacity, and reimbursement hurdles
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Definium Therapeutics, Inc. 8-K filings
Get the next DFTX 8-K as it lands
Follow DFTX for push alerts, or ask the research agent what this filing means.